Evidence map›Paper›PMID 26849135›Full record

ArticlePloS one2016

Differences in the Comparative Stability of Ebola Virus Makona-C05 and Yambuku-Mayinga in Blood.

Michael Schuit, David M Miller, Mary S Reddick-Elick, Carly B Wlazlowski, Claire Marie Filone, Artemas Herzog, Leremy A Colf, Victoria Wahl-Jensen, Michael Hevey, James W Noah

Abstract readComparative Study
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael SchuitNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
David M MillerNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
Mary S Reddick-ElickNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
Carly B WlazlowskiNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
Claire Marie FiloneNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
Artemas HerzogCenseo Consulting Group, Washington, DC, United States of America.
Leremy A ColfDepartment of Homeland Security (DHS) Science and Technology Directorate, Washington, DC, United States of America.
Victoria Wahl-JensenNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
Michael HeveyNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.
James W NoahNational Biodefense Analysis and Countermeasures Center, Frederick, MD, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In support of the response to the 2013-2016 Ebola virus disease (EVD) outbreak in Western Africa, we investigated the persistence of Ebola virus/H.sapiens-tc/GIN/2014/Makona-C05 (EBOV/Mak-C05) on non-porous surfaces that are representative of hospitals, airplanes, and personal protective equipment. We performed persistence studies in three clinically-relevant human fluid matrices (blood, simulated vomit, and feces), and at environments representative of in-flight airline passenger cabins, environmentally-controlled hospital rooms, and open-air Ebola treatment centers in Western Africa. We also compared the surface stability of EBOV/Mak-C05 to that of the prototype Ebola virus/H.sapiens-tc/COD/1976/Yambuku-Mayinga (EBOV/Yam-May), in a subset of these conditions. We show that on inert, non-porous surfaces, EBOV decay rates are matrix- and environment-dependent. Among the clinically-relevant matrices tested, EBOV persisted longest in dried human blood, had limited viability in dried simulated vomit, and did not persist in feces. EBOV/Mak-C05 and EBOV/Yam-May decay rates in dried matrices were not significantly different. However, during the drying process in human blood, EBOV/Yam-May showed significantly greater loss in viability than EBOV/Mak-C05 under environmental conditions relevant to the outbreak region, and to a lesser extent in conditions relevant to an environmentally-controlled hospital room. This factor may contribute to increased communicability of EBOV/Mak-C05 when surfaces contaminated with dried human blood are the vector and may partially explain the magnitude of the most recent outbreak, compared to prior outbreaks. These EBOV persistence data will improve public health efforts by informing risk assessments, structure remediation decisions, and response procedures for future EVD outbreaks.

Indexed as

AnimalsBloodChlorocebus aethiopsEbolavirusFecesHumansHumidityPersonal Protective EquipmentSpecies SpecificityVero CellsVomiting

Identifiers

PMID26849135
PMCPMC4744009

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.